UK markets open in 3 hours 8 minutes
  • NIKKEI 225

    28,482.05
    +662.72 (+2.38%)
     
  • HANG SENG

    20,098.22
    +15.79 (+0.08%)
     
  • CRUDE OIL

    93.86
    -0.48 (-0.51%)
     
  • GOLD FUTURES

    1,806.60
    -0.60 (-0.03%)
     
  • DOW

    33,336.67
    +27.16 (+0.08%)
     
  • BTC-GBP

    19,693.90
    -369.72 (-1.84%)
     
  • CMC Crypto 200

    570.67
    -4.08 (-0.71%)
     
  • ^IXIC

    12,779.91
    -74.89 (-0.58%)
     
  • ^FTAS

    4,131.26
    -19.42 (-0.47%)
     

Boehringer Ingelheim and F. Hoffman La Roche Among Key Players in the Idiopathic Pulmonary Fibrosis Market | GlobalData Plc

  • Oops!
    Something went wrong.
    Please try again later.
·9-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
GlobalData UK Ltd
GlobalData UK Ltd

The late-stage pipeline also features several relative newcomers, including Fibrogen, Liminal Biosciences, and PharmAkea

LONDON, July 14, 2022 (GLOBE NEWSWIRE) -- The “Idiopathic Pulmonary Fibrosis – Opportunity Analysis and Forecasts to 2029 (Event Driven Update)” report offered by GlobalData Plc provides an overview of Idiopathic Pulmonary Fibrosis (IPF) including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. The report also sheds light on topline IPF market revenue, the annual cost of therapy, and major pipeline product sales in the forecast period. Moreover, it analyzes the current and future market competition in the global IPF therapeutics market by providing an insightful review of the key industry drivers, restraints, and challenges.

The total sales of IPF therapies in the 7MM was estimated to be $2.5 billion in 2019 and is expected to increase at a CAGR of more than 4% by 2029. The US is the largest IPF market, with the highest number of diagnosed prevalent cases. The launches of five new branded pipeline agents (pamrevlumab, PRM-151, TD-139/GB-0139, CC-90001, PBI-4050) are expected to contribute to the growth of the IPF market.

To get comprehensive statistics on IPF market sizing and forecast, download a sample report

Idiopathic Pulmonary Fibrosis Market Drivers

  • The launches of five new branded pipeline agents (pamrevlumab, PRM-151, TD-139/GB-0139, CC-90001, PBI-4050) are expected to contribute to the growth of the IPF market.

  • The acknowledgment of the lucrative IPF therapeutic market by pharmaceutical companies looking to meet the series of clinical unmet needs is another market driver. These include both larger and smaller biotechnology companies alike. Drug developers now see the IPF market as one with commercial promise.

For more insights on IPF market drivers and challenges, download a sample report

Idiopathic Pulmonary Fibrosis Market - Unmet Needs and Opportunity Assessment

IPF remains an area of high unmet clinical need. Based on the heterogeneous nature of IPF, a series of unknowns exist, within the pathophysiology of the disease itself and with how it progresses within individual patients. This variability can impact how the disease is diagnosed and how patients respond to treatment. As a result of these unknowns relating to the disease and its complexity, IPF was largely overlooked by pharmaceutical companies until recently. Thus, there are only two approved treatments -Esbriet and Ofev. Over the ten-year forecast period, the IPF market is expected to evolve due to the improvements offered by pipeline products. In turn, this will address a number of pressing unmet needs that the disease currently exhibits, ultimately creating hope for an improved prognosis for IPF patients.

For more insights on unmet needs and opportunities in the IPF market, download a sample report

Idiopathic Pulmonary Fibrosis Market - Competitive Landscape

Due to their success with Ofev and Esbriet, respectively, Boehringer Ingelheim and F. Hoffman La Roche have historically been key players in the IPF market space, and this is likely to continue throughout the first half of the forecast period. Notably, the late-stage pipeline also features several relative newcomers, including Fibrogen, Liminal Biosciences, and PharmAkea.

Leading Companies in the Idiopathic Pulmonary Fibrosis Market

  • Boehringer Ingelheim

  • F. Hoffman La Roche

  • Fibrogen

  • Liminal Biosciences

  • PharmAkea Therapeutics

To know more about leading companies in the IPF Market, download a sample report

Idiopathic Pulmonary Fibrosis Market Report Scope

  • Overview of IPF including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

  • Topline IPF market revenue, the annual cost of therapy, and major pipeline product sales in the forecast period.

  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting IPF therapeutics sales in the 7MM.

  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

  • Analysis of the current and future market competition in the global IPF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.

  • Develop business strategies by understanding the trends shaping and driving the global IPF therapeutics market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global IPF market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

  • Track drug sales in the global IPF therapeutics market from 2019-2029.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Related Reports

  • Lung Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type, and Key Players – Click here

  • Metastatic Melanoma Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update – Click here

  • Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape – Click here

  • Lung Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type, and Key Players – Click here

  • Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type, and Key Players – Click here

Idiopathic Pulmonary Fibrosis Market Overview

Market Size 2019

$2.5 Billion

CAGR

>4%

Forecast Period

2019-2029

Leading Companies

Boehringer Ingelheim, F. Hoffman La Roche, Fibrogen, Liminal Biosciences, and PharmAkea

FAQs

What was the idiopathic pulmonary fibrosis market size in 2019?
The IPF market size was valued at $2.5 billion in 2019.

What is the idiopathic pulmonary fibrosis market growth rate?
The IPF market is projected to grow at a CAGR of more than 4% during the forecast period, 2019-2029.

Which are the leading companies in the idiopathic pulmonary fibrosis market?
Some of the leading companies in the IPF market are Boehringer Ingelheim, F. Hoffman La Roche, Fibrogen, Liminal Biosciences, and PharmAkea Therapeutics.

Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Idiopathic Pulmonary Fibrosis: Executive Summary

2.1 IPF Market to Experience Conservative Growth over the Forecast Period

2.2 Innovative Small Pharma Require Partnerships to Sustain Development

2.3 High Unmet Clinical Needs Remain

2.4 Late-Stage Pipeline Fractured Among Many Differing Mechanisms of Action

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification or Staging Systems

4.2.1 GAP Model

4.2.2 Stratification by Decline in Forced Vital Capacity (FVC)

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources Used

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for IPF (2019-2029)

5.5.1 Diagnosed Incident Cases of IPF

5.5.2 Sex-Specific Diagnosed Incident Cases of IPF

5.5.3 Age-Specific Diagnosed Incident Cases of IPF

5.5.4 Diagnosed Prevalent Cases of IPF

5.5.5 Sex-Specific Diagnosed Prevalent Cases of IPF

5.5.6 Age-Specific Diagnosed Prevalent Cases of IPF

5.5.7 Diagnosed Prevalent Cases of IPF by Severity

5.5.8 Diagnosed Prevalent Cases of IPF by Comorbidities

5.5.9 Total Prevalent Cases of IPF

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Coronavirus Disease 2019 (COVID-19) Impact

5.6.3 Limitations of Analysis

5.6.4 Strengths of Analysis

6 Current Treatment Options

6.1 Overview

6.2 Current Treatment Guidelines

6.3 Symptomatic Treatments

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Earlier Diagnosis

7.3 Improved Drug Safety and Efficacy

7.4 Improvement in Patient Quality of Life

7.5 Treatments for Patients with Severe Disease

8 R&D Strategies

8.1 Overview

8.1.1 Corporate Partnerships

8.1.2 Combination Therapy

8.2 Clinical Trial Design

8.2.1 Appropriate Endpoints

8.2.2 Increased Use of Quality of Life Measures

8.2.3 Add-Ons to Standard of Care

8.2.4 Selection of Patient Population

9 Impact of COVID-19 on the IPF Disease Space

9.1 Overview

9.2 Continuity of Care

9.3 Trial Logistics

9.3.1 Recruitment

9.3.2 Trial Conduct in Isolation

9.3.3 Supply Chain

9.4 Long-Term Impact on the Disease Space

10 Pipeline Assessment

10.1 Overview

10.2 Innovative Early-Stage Approaches

11 Pipeline Valuation Analysis

11.1 Clinical Benchmark of Key Pipeline Drugs

11.2 Commercial Benchmark of Key Pipeline Drugs

11.3 Competitive Assessment

11.4 Top-Line 10-Year Forecast

11.4.1 US

11.4.2 5EU

11.4.3 Japan

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research – KOLs Interviewed for This Report

12.4.1 KOLs

12.4.2 Payers

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

About us

GlobalData is a leading provider of data, analytics, and insights on the world's largest industries. In an increasingly fast-moving, complex, and uncertain world, it has never been harder for organizations and decision makers to predict and navigate the future. This is why GlobalData's mission is to help our clients to decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on GlobalData for trusted, timely, and actionable intelligence. Our solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies.

Media Contacts

GlobalData

Mark Jephcott
Head of PR EMEA
mark.jephcott@globaldata.com
cc: pr@globaldata.com

+44 (0)207 936 6400



Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting